Incidence of hospital-acquired acute kidney injury and trajectories of glomerular filtration rate in older adults

Autor: Natalie Ebert, Alice Schneider, Doerte Huscher, Nina Mielke, Yanina Balabanova, Gunnar Brobert, Carla Lakenbrink, Martin Kuhlmann, Anne-Katrin Fietz, Markus van der Giet, Volker Wenning, Elke Schaeffner

Publikováno v: BMC Nephrology, Vol 24, Iss 1, Pp 1-10 (2023)

Abstract Background In older adults, epidemiological data on incidence rates (IR) of hospital-acquired acute kidney injury (AKI) are scarce. Also, little is known about trajectories of kidney function before hospitalization with AKI. Methods We used

Externí odkaz: https://doaj.org/article/9fe037c1fb004dffa5d77cd9ab8af48a

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

Autor: Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez

Publikováno v: PLoS ONE, Vol 19, Iss 3, p e0298596 (2024)

BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical pract

Externí odkaz: https://doaj.org/article/21563d3bc5d248d7917f16c59b0f6158

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden

Autor: Yanina Balabanova, Bahman Farahmand, Pär Stattin, Hans Garmo, Gunnar Brobert

Publikováno v: BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)

Abstract Background Epidemiological data on anticoagulation for venous thromboembolism (VTE) in prostate cancer are sparse. We aimed to investigate associations between anticoagulation duration and risks of VTE recurrence after treatment cessation an

Externí odkaz: https://doaj.org/article/1e963667535e4f41a88d0d4127aa4d16

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries

Autor: Luis Alberto García Rodríguez, Ana Ruigómez, Tania Schink, Annemarie Voss, Elisabeth Smits, Karin M. A. Swart, Yanina Balabanova, Kiliana Suzart-Woischnik, Gunnar Brobert, Ron M. C. Herings

Publikováno v: García-Rodríguez, L A, Ruigómez, A, Schink, T, Voss, A, Smits, E, Swart, K M A, Balabanova, Y, Suzart-Woischnik, K, Brobert, G & Herings, R M C 2023, ' Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation : analysis of routine clinical data from four countries ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2023.2181334
Expert opinion on drug safety. Taylor and Francis Ltd.

Background: The safety and effectiveness of rivaroxaban versus vitamin K antagonists (standard of care [SOC]) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) was evaluated in Europe. Research design and methods: Observat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca27dc1f96c0361f2e9c0a5ea231d0e
https://doi.org/10.1080/14740338.2023.2181334

Pre‐ and post‐stroke oral antithrombotics and mortality in patients with ischaemic stroke

Autor: Luis A. García Rodríguez, David Gaist, Yanina Balabanova, Gunnar Brobert, Mike Sharma, Lucía Cea Soriano

Publikováno v: Pharmacoepidemiology and Drug Safety. 31:1182-1189

Reducing stroke occurrence requires the effective management of cardiovascular and other stroke risk factors.To describe pre- and post-stroke medication use, focusing on antithrombotic therapy and mortality risk, in individuals hospitalised for ischa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99b65922c1529c1654328728a687a88
https://doi.org/10.1002/pds.5530